Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review

Figure 3 Non-alcoholic fatty liver disease fibrosis score: Components and interpretation flowchart. Flowchart summarizing the non-alcoholic fatty liver disease fibrosis score, which incorporates age, body mass index, fasting glucose or diabetes status, aspartate aminotransferase/alanine aminotransferase ratio, platelet count, and serum albumin. This tool stratifies patients by fibrosis risk: Values < -1.455 suggest low risk, > 0.675 indicate high risk, and intermediate values require further evaluation. The non-alcoholic fatty liver disease fibrosis score is widely used for non-invasive fibrosis screening in metabolic dysfunction-associated steatotic liver disease, especially in primary care. NAFLD: Non-alcoholic fatty liver disease; BMI: Body mass index; IFG: Impaired fasting glucose; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.